Ultrahigh-field cardiovascular magnetic resonance T1 and T2 mapping for the assessment of anthracycline-induced cardiotoxicity in rat models: validation against histopathologic changes

Abstract Background Chemotherapy-induced cardiotoxicity is a well-recognized adverse effect of chemotherapy. Quantitative T1-mapping cardiovascular magnetic resonance (CMR) is useful for detecting subclinical myocardial changes in anthracycline-induced cardiotoxicity. The aim of the present study wa...

Full description

Bibliographic Details
Main Authors: Heae Surng Park, Yoo Jin Hong, Kyunghwa Han, Pan Ki Kim, Eunkyung An, Ji Yeon Lee, Chul Hwan Park, Hye-Jeong Lee, Jin Hur, Young Jin Kim, Byoung Wook Choi
Format: Article
Language:English
Published: BMC 2021-06-01
Series:Journal of Cardiovascular Magnetic Resonance
Subjects:
Online Access:https://doi.org/10.1186/s12968-021-00767-8
id doaj-5a775173c5c640348acfbb51725991fb
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Heae Surng Park
Yoo Jin Hong
Kyunghwa Han
Pan Ki Kim
Eunkyung An
Ji Yeon Lee
Chul Hwan Park
Hye-Jeong Lee
Jin Hur
Young Jin Kim
Byoung Wook Choi
spellingShingle Heae Surng Park
Yoo Jin Hong
Kyunghwa Han
Pan Ki Kim
Eunkyung An
Ji Yeon Lee
Chul Hwan Park
Hye-Jeong Lee
Jin Hur
Young Jin Kim
Byoung Wook Choi
Ultrahigh-field cardiovascular magnetic resonance T1 and T2 mapping for the assessment of anthracycline-induced cardiotoxicity in rat models: validation against histopathologic changes
Journal of Cardiovascular Magnetic Resonance
Magnetic resonance imaging
Myocardial fibrosis
Edema
Inflammation
T1 mapping
Cardiotoxicity
author_facet Heae Surng Park
Yoo Jin Hong
Kyunghwa Han
Pan Ki Kim
Eunkyung An
Ji Yeon Lee
Chul Hwan Park
Hye-Jeong Lee
Jin Hur
Young Jin Kim
Byoung Wook Choi
author_sort Heae Surng Park
title Ultrahigh-field cardiovascular magnetic resonance T1 and T2 mapping for the assessment of anthracycline-induced cardiotoxicity in rat models: validation against histopathologic changes
title_short Ultrahigh-field cardiovascular magnetic resonance T1 and T2 mapping for the assessment of anthracycline-induced cardiotoxicity in rat models: validation against histopathologic changes
title_full Ultrahigh-field cardiovascular magnetic resonance T1 and T2 mapping for the assessment of anthracycline-induced cardiotoxicity in rat models: validation against histopathologic changes
title_fullStr Ultrahigh-field cardiovascular magnetic resonance T1 and T2 mapping for the assessment of anthracycline-induced cardiotoxicity in rat models: validation against histopathologic changes
title_full_unstemmed Ultrahigh-field cardiovascular magnetic resonance T1 and T2 mapping for the assessment of anthracycline-induced cardiotoxicity in rat models: validation against histopathologic changes
title_sort ultrahigh-field cardiovascular magnetic resonance t1 and t2 mapping for the assessment of anthracycline-induced cardiotoxicity in rat models: validation against histopathologic changes
publisher BMC
series Journal of Cardiovascular Magnetic Resonance
issn 1532-429X
publishDate 2021-06-01
description Abstract Background Chemotherapy-induced cardiotoxicity is a well-recognized adverse effect of chemotherapy. Quantitative T1-mapping cardiovascular magnetic resonance (CMR) is useful for detecting subclinical myocardial changes in anthracycline-induced cardiotoxicity. The aim of the present study was to histopathologically validate the T1 and T2 mapping parameters for the evaluation of diffuse myocardial changes in rat models of cardiotoxicity. Methods Rat models of cardiotoxicity were generated by injecting rats with doxorubicin (1 mg/kg, twice a week). CMR was performed with a 9.4 T ultrahigh-field scanner using cine, pre-T1, post-T1 and T2 mapping sequences to evaluate the left ventricular ejection fraction (LVEF), native T1, T2, and extracellular volume fraction (ECV). Histopathological examinations were performed and the association of histopathological changes with CMR parameters was assessed. Results Five control rats and 36 doxorubicin-treated rats were included and classified into treatment periods. In the doxorubicin-treated rats, the LVEF significantly decreased after 12 weeks of treatment (control vs. 12-week treated: 73 ± 4% vs. 59 ± 9%, P = 0.01).  Increased native T1 and ECV were observed after 6 weeks of treatment (control vs. 6-week treated: 1148 ± 58 ms, 14.3 ± 1% vs. 1320 ± 56 ms, 20.3 ± 3%; P = 0.005, < 0.05, respectively). T2 values also increased by six weeks of treatment (control vs. 6-week treated: 16.3 ± 2 ms vs. 10.3 ± 1 ms, P < 0.05). The main histopathological features were myocardial injury, interstitial fibrosis, inflammation, and edema. The mean vacuolar change (%), fibrosis (%), and inflammation score were significantly higher in 6-week treated rats than in the controls (P = 0.03, 0.03, 0.02, respectively). In the univariable analysis, vacuolar change showed the highest correlation with native T1 value (R = 0.60, P < 0.001), and fibrosis showed the highest correlation with ECV value (R = 0.78, P < 0.001). In the multiple linear regression analysis model, vacuolar change was a significant factor for change in native T1 (P = 0.01), and vacuolar change and fibrosis were significant factors for change in ECV (P = 0.006, P < 0.001, respectively) by adding other histopathological parameters (i.e., inflammation and edema scores) Conclusions Quantitative T1 and T2 mapping CMR is a useful non-invasive tool reflecting subclinical histopathological changes in anthracycline-induced cardiotoxicity.
topic Magnetic resonance imaging
Myocardial fibrosis
Edema
Inflammation
T1 mapping
Cardiotoxicity
url https://doi.org/10.1186/s12968-021-00767-8
work_keys_str_mv AT heaesurngpark ultrahighfieldcardiovascularmagneticresonancet1andt2mappingfortheassessmentofanthracyclineinducedcardiotoxicityinratmodelsvalidationagainsthistopathologicchanges
AT yoojinhong ultrahighfieldcardiovascularmagneticresonancet1andt2mappingfortheassessmentofanthracyclineinducedcardiotoxicityinratmodelsvalidationagainsthistopathologicchanges
AT kyunghwahan ultrahighfieldcardiovascularmagneticresonancet1andt2mappingfortheassessmentofanthracyclineinducedcardiotoxicityinratmodelsvalidationagainsthistopathologicchanges
AT pankikim ultrahighfieldcardiovascularmagneticresonancet1andt2mappingfortheassessmentofanthracyclineinducedcardiotoxicityinratmodelsvalidationagainsthistopathologicchanges
AT eunkyungan ultrahighfieldcardiovascularmagneticresonancet1andt2mappingfortheassessmentofanthracyclineinducedcardiotoxicityinratmodelsvalidationagainsthistopathologicchanges
AT jiyeonlee ultrahighfieldcardiovascularmagneticresonancet1andt2mappingfortheassessmentofanthracyclineinducedcardiotoxicityinratmodelsvalidationagainsthistopathologicchanges
AT chulhwanpark ultrahighfieldcardiovascularmagneticresonancet1andt2mappingfortheassessmentofanthracyclineinducedcardiotoxicityinratmodelsvalidationagainsthistopathologicchanges
AT hyejeonglee ultrahighfieldcardiovascularmagneticresonancet1andt2mappingfortheassessmentofanthracyclineinducedcardiotoxicityinratmodelsvalidationagainsthistopathologicchanges
AT jinhur ultrahighfieldcardiovascularmagneticresonancet1andt2mappingfortheassessmentofanthracyclineinducedcardiotoxicityinratmodelsvalidationagainsthistopathologicchanges
AT youngjinkim ultrahighfieldcardiovascularmagneticresonancet1andt2mappingfortheassessmentofanthracyclineinducedcardiotoxicityinratmodelsvalidationagainsthistopathologicchanges
AT byoungwookchoi ultrahighfieldcardiovascularmagneticresonancet1andt2mappingfortheassessmentofanthracyclineinducedcardiotoxicityinratmodelsvalidationagainsthistopathologicchanges
_version_ 1721369738579279872
spelling doaj-5a775173c5c640348acfbb51725991fb2021-06-20T11:44:53ZengBMCJournal of Cardiovascular Magnetic Resonance1532-429X2021-06-0123111310.1186/s12968-021-00767-8Ultrahigh-field cardiovascular magnetic resonance T1 and T2 mapping for the assessment of anthracycline-induced cardiotoxicity in rat models: validation against histopathologic changesHeae Surng Park0Yoo Jin Hong1Kyunghwa Han2Pan Ki Kim3Eunkyung An4Ji Yeon Lee5Chul Hwan Park6Hye-Jeong Lee7Jin Hur8Young Jin Kim9Byoung Wook Choi10Department of Pathology, Ewha Womans University Seoul HospitalDepartment of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine, Severance HospitalDepartment of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine, Severance HospitalDepartment of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine, Severance HospitalDepartment of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine, Severance HospitalDepartment of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine, Severance HospitalDepartment of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine, Gangnam Severance HospitalDepartment of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine, Severance HospitalDepartment of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine, Severance HospitalDepartment of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine, Severance HospitalDepartment of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine, Severance HospitalAbstract Background Chemotherapy-induced cardiotoxicity is a well-recognized adverse effect of chemotherapy. Quantitative T1-mapping cardiovascular magnetic resonance (CMR) is useful for detecting subclinical myocardial changes in anthracycline-induced cardiotoxicity. The aim of the present study was to histopathologically validate the T1 and T2 mapping parameters for the evaluation of diffuse myocardial changes in rat models of cardiotoxicity. Methods Rat models of cardiotoxicity were generated by injecting rats with doxorubicin (1 mg/kg, twice a week). CMR was performed with a 9.4 T ultrahigh-field scanner using cine, pre-T1, post-T1 and T2 mapping sequences to evaluate the left ventricular ejection fraction (LVEF), native T1, T2, and extracellular volume fraction (ECV). Histopathological examinations were performed and the association of histopathological changes with CMR parameters was assessed. Results Five control rats and 36 doxorubicin-treated rats were included and classified into treatment periods. In the doxorubicin-treated rats, the LVEF significantly decreased after 12 weeks of treatment (control vs. 12-week treated: 73 ± 4% vs. 59 ± 9%, P = 0.01).  Increased native T1 and ECV were observed after 6 weeks of treatment (control vs. 6-week treated: 1148 ± 58 ms, 14.3 ± 1% vs. 1320 ± 56 ms, 20.3 ± 3%; P = 0.005, < 0.05, respectively). T2 values also increased by six weeks of treatment (control vs. 6-week treated: 16.3 ± 2 ms vs. 10.3 ± 1 ms, P < 0.05). The main histopathological features were myocardial injury, interstitial fibrosis, inflammation, and edema. The mean vacuolar change (%), fibrosis (%), and inflammation score were significantly higher in 6-week treated rats than in the controls (P = 0.03, 0.03, 0.02, respectively). In the univariable analysis, vacuolar change showed the highest correlation with native T1 value (R = 0.60, P < 0.001), and fibrosis showed the highest correlation with ECV value (R = 0.78, P < 0.001). In the multiple linear regression analysis model, vacuolar change was a significant factor for change in native T1 (P = 0.01), and vacuolar change and fibrosis were significant factors for change in ECV (P = 0.006, P < 0.001, respectively) by adding other histopathological parameters (i.e., inflammation and edema scores) Conclusions Quantitative T1 and T2 mapping CMR is a useful non-invasive tool reflecting subclinical histopathological changes in anthracycline-induced cardiotoxicity.https://doi.org/10.1186/s12968-021-00767-8Magnetic resonance imagingMyocardial fibrosisEdemaInflammationT1 mappingCardiotoxicity